Rare endocrine and metabolic diseases, hypoparathyroidism; syndromes of severe insulin resistance; lipodystrophy

Alizé Pharma 3 develops innovative therapeutic peptides for rare endocrine and metabolic diseases. Its ambition is to become a leading company in rare diseases with operations in both the US and Europe to support the global development of products.
Alizé Pharma 3 is building an innovative and balanced portfolio of products targeting significant unmet medical needs. Its first two assets are AZP-3601, a best-in-class PTH analog for hypoparathyroidism, and AZP-3404, a peptide leveraging the biology of IGFBP2 for the treatment of syndromes of severe insulin resistance.